Membrane fusogenic nanoparticle-based HLA-peptide-addressing universal T cell receptor-engineered T (HAUL TCR-T) cell therapy in solid tumor

• Published in: Bioengineering & translational medicine Vol. 8; no. 6; pp. e10585 - n/a
• Main Authors: Xu, Ruihan, Wang, Qin, Zhu, Junmeng, Bei, Yuncheng, Chu, Yanhong, Sun, Zhichen, Du, Shiyao, Zhou, Shujuan, Ding, Naiqing, Meng, Fanyan, Liu, Baorui
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.11.2023; Wiley
• Subjects: Antigens; Cell membranes; Cytotoxicity; Flow cytometry; HLA‐peptide complex; Leukocytes; Lipids; Lymphocytes; membrane fusogenic nanoparticles; Microscopy; Nanoparticles; Penicillin; Peptides; Receptors; solid tumors; T cell receptors; TCR‐T cell therapy; Therapy; tumor cell membrane modification; Tumors; United Kingdom > UK; United States > US; Germany; membrane fusogenic nanoparticles; TCR‐T cell therapy; tumor cell membrane modification; HLA‐peptide complex; solid tumors
• ISSN: 2380-6761; 2380-6761
• DOI: 10.1002/btm2.10585

T cell receptor-engineered T (TCR-T) cell therapy has demonstrated therapeutic effects in basic research and clinical trials for treating solid tumors. Due to the peptide-dependent recognition and the human leukocyte antigen (HLA)-restriction, TCR-T cell therapy is generally custom designed to target individual antigens. The lack of suitable universal targets for tumor cells significantly limits its clinical applications. Establishing a universal TCR-T treatment strategy is of great significance. This study designed and evaluated the HLA-peptide-addressing universal (HAUL) TCR-T cell therapy based on HLA-peptide (pHLA) loaded membrance fusogenic deliver system. The pHLA-NP-based tumor cell membrane modification technology can transfer the pHLA onto the surface of tumor cells through membrane fusogenic nanoparticles. Then tumor cells are recognized and killed by TCR-T cells specifically. The HAUL TCR-T cell therapy technology is a universal technology that enables tumor cells to be identified and killed by specific TCR-T cells, regardless of the HLA typing of tumor cells.